Lower Lenvatinib Starting Doses Show No Clear Advantage in Advanced Endometrial Cancer
A new systematic review and meta-analysis finds that starting lenvatinib below 20 mg with pembrolizumab neither clearly preserves tumor response ...
A new systematic review and meta-analysis finds that starting lenvatinib below 20 mg with pembrolizumab neither clearly preserves tumor response ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine